<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: More than half of patients with KRAS-<z:mp ids='MP_0002169'>wild type</z:mp> advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) fail anti-EGFR monoclonal antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>We studied EGFR-axis <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) expression and <z:mp ids='MP_0011356'>RAS</z:mp>, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Previously genotyped (KRAS, NRAS, BRAF, PIK3CA mutations) formalin-fixed paraffin-embedded <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> biopsies of 226 cetuximab-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (1st to 3rd line therapy) were assessed for <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of epidermal growth factor receptor (EGFR) and its ligands EGF, Transofrming Growth Factor-a (TGFA), Amphiregulin (AREG) and Epiregulin (EREG) with real time quantitative PCR </plain></SENT>
<SENT sid="3" pm="."><plain>Mutations were detected in 72 (31.9%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> for KRAS, in 6 (2.65%) for BRAF, in 7 (3.1%) for NRAS and in 37 (16.4%) for PIK3CA </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Only PIK3CA mutations occasionally coexisted with other gene mutations </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate analysis, prognostic significance for survival ( from <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> until <z:hpo ids='HP_0011420'>death</z:hpo>) was seen for BRAF mutations (Hazard Ratio HR 8.1, 95% CI 3.4-19), codon 12-only KRAS mutations (HR 1.62, 95% CI 1.1-2.4), high AREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression only in KRAS <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (HR 0.47, 95% CI 0.3-0.7) and high EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression irrespective of KRAS mutation status (HR 0.45, 95% CI 0.28-0.7) </plain></SENT>
<SENT sid="6" pm="."><plain>EREG tumoural <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly associated with a 2.26-fold increased likelihood of objective response to cetuximab therapy (RECIST 1.1) </plain></SENT>
<SENT sid="7" pm="."><plain>In multivariate analysis, favourable predictive factors were high AREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> in KRAS <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, high EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi>, low Ephrin A2 receptor <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Cetuximab-treated patients with AREG-low KRAS <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> fared very poorly, their survival being similar to KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with KRAS codon 13 or other non-codon 12 mutations had a median survival (30 months, 95% CI 20-35) similar to that of patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> (median survival 29 months, 95% CI 25-35), in contrast to patients with KRAS codon 12 mutations who fared worse (median survival 19 months, 95% CI 15-26) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: BRAF and codon 12 KRAS mutations predict for adverse outcome of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients receiving cetuximab </plain></SENT>
<SENT sid="11" pm="."><plain>AREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> reflects EGFR signalling in KRAS <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, predicting for cetuximab efficacy when high and failure when low </plain></SENT>
<SENT sid="12" pm="."><plain>EREG may have a prognostic role independent of KRAS mutation </plain></SENT>
</text></document>